Retrospective Analysis of Clinico-Epidimological Factors in Prostatic Cancer | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 16, Volume 73, Issue 2, October 2018, Page 6075-6081 PDF (390.27 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2018.12518 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Atef Youssef Reyad; Mai Mohamed Ezz El Din; Nesreen Ahmed Mosalam; Walaa Hatem El Damhogy 
| ||||
| Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University | ||||
| Abstract | ||||
| Background: Prostate cancer is the second most common cancer in men and the seventh leading cause of male cancer death worldwide. It is a highly heterogenous disease with great variability in its clinical course. Treatment options vary depending on age, stage, and grade of cancer, as well as other medical conditions. Aim of study: In this retrospective study we aimed to provide clinico-epidemiological characteristics of prostate cancer and to present different treatment modalities with respect to OS, DFS and PFS. Patients and Methods: Male patients with localized or metastatic prostate cancer presented to Ain Shams University Hospitals in the period from January 2010, to December 2015. In our study, we reviewed medical records of 101 patients including demographic data and clinic-pathological factors were reported, including age, sex, performance status (ECOG), co-morbidities, personal habits, tumor characteristics, surgery, radical treatment, metastatic treatment, treatment response and survival rates were collected. Results: Our population under study had a median age of 69 years (range: 42-85), majority of our patients (94%) had good ECOG performance status (≤ 2), (44.6%) of the patients were presented to us with metastatic disease, most common symptoms at presentation were prostatism in 72.8% of patients and bony aches in 18.8%. The mean Gleason score among studied population was mean 7.37. 44.6% of the patients were metastatic at time of presentation. Median overall survival in studied population was 31 months, median PFS of the studied group was 17 months and the median DFS 29 months. Conclusion: We provide an overview of patients with prostate cancer in a single tertiary institution in Cairo and it was found that lack of patient awareness in most patients leads to their late presentation at time of diagnosis. | ||||
| Keywords | ||||
| Prostate Cancer; Diagnosis; Enzalutamide; salvage; Egypt | ||||
|
Statistics Article View: 211 PDF Download: 365 |
||||
